Clinical Trial Update: Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis [Phase 3]

View source ↗

Summary

Phase 3 study of gevokizumab for Behçet's disease–associated uveitis has been terminated, with the trial not proceeding to completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: XOMA (US) LLC | Conditions: Behcet's Disease Uveitis | Phase 3 | Status: TERMINATED